...
首页> 外文期刊>Journal of proteome research >Hyperplex-MRM: A hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker
【24h】

Hyperplex-MRM: A hybrid multiple reaction monitoring method using mTRAQ/iTRAQ labeling for multiplex absolute quantification of human colorectal cancer biomarker

机译:Hyperplex-MRM:使用mTRAQ / iTRAQ标记的混合多反应监测方法,用于人类结直肠癌生物标记物的多重绝对定量

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Novel biomarker verification assays are urgently required to improve the efficiency of biomarker development. Benefitting from lower development costs, multiple reaction monitoring (MRM) has been used for biomarker verification as an alternative to immunoassay. However, in general MRM analysis, only one sample can be quantified in a single experiment, which restricts its application. Here, a Hyperplex-MRM quantification approach, which combined mTRAQ for absolute quantification and iTRAQ for relative quantification, was developed to increase the throughput of biomarker verification. In this strategy, equal amounts of internal standard peptides were labeled with mTRAQ reagents Δ0 and Δ8, respectively, as double references, while 4-plex iTRAQ reagents were used to label four different samples as an alternative to mTRAQ Δ4. From the MRM trace and MS/MS spectrum, total amounts and relative ratios of target proteins/peptides of four samples could be acquired simultaneously. Accordingly, absolute amounts of target proteins/peptides in four different samples could be achieved in a single run. In addition, double references were used to increase the reliability of the quantification results. Using this approach, three biomarker candidates, ademosylhomocysteinase (AHCY), cathepsin D (CTSD), and lysozyme C (LYZ), were successfully quantified in colorectal cancer (CRC) tissue specimens of different stages with high accuracy, sensitivity, and reproducibility. To summarize, we demonstrated a promising quantification method for high-throughput verification of biomarker candidates.
机译:迫切需要新颖的生物标志物验证测定法,以提高生物标志物开发的效率。受益于较低的开发成本,多反应监测(MRM)已用于生物标志物验证,作为免疫测定的替代方法。但是,在一般的MRM分析中,一次实验只能定量一个样品,这限制了它的应用。在这里,开发了一种结合了用于绝对定量的mTRAQ和用于相对定量的iTRAQ的Hyperplex-MRM定量方法,以提高生物标志物验证的通量。在该策略中,等量的内标肽分别用mTRAQ试剂Δ0和Δ8标记,作为双重参照,而4-plex iTRAQ试剂用于标记四个不同的样品,以替代mTRAQΔ4。从MRM迹线和MS / MS谱图中,可以同时获取四个样品的目标蛋白/肽的总量和相对比例。因此,一次运行即可获得四个不同样品中靶蛋白/肽的绝对量。此外,还使用了双重参照来提高定量结果的可靠性。使用这种方法,已成功地在不同阶段的结直肠癌(CRC)组织标本中对三种生物标志物候选物-腺苷同型半胱氨酸酶(AHCY),组织蛋白酶D(CTSD)和溶菌酶C(LYZ)进行了定量,具有较高的准确性,灵敏度和可重复性。总而言之,我们展示了一种有前途的定量方法,可用于生物标记物候选物的高通量验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号